Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
- Registration Number
- NCT04327661
- Lead Sponsor
- Vanda Pharmaceuticals
- Brief Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 366
- History of motion sickness
- Age 18-75
- Nausea-inducing disorder other than motion sickness
- BMI>40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tradipitant Low Dose Tradipitant - Placebo Placebo - Tradipitant High Dose Tradipitant -
- Primary Outcome Measures
Name Time Method Prevention of Vomiting Measured by Vomiting Assessment (VA) 1 day Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Gulfcoast Psychiatric Associates
🇺🇸Fort Myers, Florida, United States
Pacific Research Network, LLC
🇺🇸San Diego, California, United States
Santa Monica Clinical Trials
🇺🇸Santa Monica, California, United States
Harmony Clinical Research
🇺🇸North Miami Beach, Florida, United States
Avita Clinical Research
🇺🇸Tampa, Florida, United States
Beacon Clinical Research
🇺🇸Quincy, Massachusetts, United States
Manhattan Medical Research
🇺🇸New York, New York, United States